Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 310 shares, an increase of 3,344.4% from the May 14th total of 9 shares. Based on an average trading volume of 2,834 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Enzon Pharmaceuticals Price Performance

OTCMKTS:ENZN opened at $5.75 on Wednesday. Enzon Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $12.99. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42. The stock has a market cap of $4.26 million, a price-to-earnings ratio of -0.84 and a beta of -0.06. The stock has a 50-day moving average price of $6.03 and a two-hundred day moving average price of $5.58.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its quarterly earnings data on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The firm had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.